Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Sarcoma × pexidartinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Giant Cell Tumor of Tendon Sheath 5 Synovitis, Pigmented Villonodular 3 Melanoma 2 Gastrointestinal Stromal Tumors 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Solid Tumors 1

Interventions

Doxorubicin 31 Ifosfamide 22 pazopanib 17 Gemcitabine 15 Cyclophosphamide 14 Radiotherapy 13 pembrolizumab 11 Filgrastim 10 Docetaxel 10 Vincristine 9 Sirolimus 9 Etoposide 9 Irinotecan 8 Bevacizumab 8 Sorafenib 7 temsirolimus 6 olaratumab 6 eribulin 6 Mesna 6 cixutumumab 5 Trabectedin 5 Radiosurgery 5 Radiation 5 Magnetic Resonance Spectroscopy 5 Granulocyte Colony-Stimulating Factor 5 tazemetostat 4 etoposide phosphate 4 Temozolomide 4 Nivolumab 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡